CATXHIGH SIGNALFINANCIAL10-K

CATX faces deteriorating financial position with cash reserves cut in half, mounting losses, and substantially higher current liabilities amid continued heavy operating deficits.

The company's cash position dropped from $61.6M to $30.6M while current liabilities increased meaningfully to $28.7M, creating potential liquidity pressure for this clinical-stage biotech. Combined with widening net losses exceeding $100M annually, CATX appears to be burning through capital at an unsustainable rate that could necessitate additional financing in the near term.

Comparing 2026-03-16 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

CATX shows signs of financial stress with cash reserves declining by over 50% to $30.6M while current liabilities grew substantially to $28.7M, compressing working capital. Operating losses widened to $113.6M despite modest revenue growth to $5.9M, indicating the company remains heavily dependent on external financing. The sharp reduction in capital expenditures from $54.4M to $12.7M suggests potential scaling back of development activities, while stockholders' equity declined to $207.0M as accumulated losses mount.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-94.8%
$116K→$6K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-76.6%
$54.4M→$12.7M

Capex reduced 76.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+57.3%
$18.2M→$28.7M

Current liabilities surged 57.3% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-50.3%
$61.6M→$30.6M

Cash declined 50.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Inventory
Balance Sheet
+42.4%
$980K→$1.4M

Inventory surged 42.4% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
-35.8%
$231.2M→$148.4M

Current assets declined 35.8% — monitor working capital adequacy and short-term liquidity.

Net Income
P&L
-30.1%
-$79.3M→-$103.1M

Net income declined 30.1% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-28.8%
$290.7M→$207.0M

Equity decreased 28.8% — buybacks or losses reducing book value, monitor solvency ratios.

Operating Income
P&L
-25%
-$90.9M→-$113.6M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Revenue
P&L
+24.4%
$4.8M→$5.9M

Revenue growing 24.4% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-26
ADDED
and international trade policies, including tariffs, on our costs for supplies, equipment and materials used in the development and production of our targeted alpha therapy drug product candidates; and expectations, beliefs, intentions and strategies regarding the future.
Disruptions at the FDA, including due to a lapse in appropriations and/or decreased funding for the FDA, could prevent the FDA from performing functions on which our business relies, which could negatively impact our business.
We receive federal funding to conduct certain research on our product candidates and other programs, and recent federal policy changes could disrupt that funding.
If we are unable to execute our sales and marketing strategy for our product candidates, if commercialized, and are unable to gain market acceptance, we may be unable to generate sufficient revenue to sustain our business.
We may rely partially on third parties to manufacture our clinical pharmaceutical supplies and could continue to rely on third parties to produce commercial supplies of any approved product candidate, and our dependence on third party suppliers could adversely impact our business.
+7 more — sign up free →
REMOVED
These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances.
AVAILABLE INFORMATION As soon as reasonably practicable after they are filed electronically with the SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, other SEC filings and amendments to those reports are available without charge on our website, www.perspectivetherapeutics.com, which we also use to announce material information to the public.
We are providing the address to our website solely for the information of investors.
We do not intend the address to be an active link or to otherwise incorporate the contents of the website into this Form 10-K.
SUMMARY OF RISK FACTORS Investing in our common stock involves significant risks.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →